Development of Selective SsDNA Micro-probe for PD1 Detection As a Novel Strategy for Cancer Imaging

Overview

Journal Sci Rep

Specialty Science

Date 2024 Nov 20

PMID 39562585

Authors

Stanislaw Malicki

Anna Czarna

Edyta Zyla

Barbara Pucelik

Wojciech Galan

Barbara Chruscicka

Marta Kaminska

Alicja Sochaj-Gregorczyk

Katarzyna Magiera-Mularz

Jun Wang

Marek Winiarski

Malgorzata Benedyk-Machaczka

Joanna Koziel

Grzegorz Dubin

Piotr Mydel

Affiliations

Soon will be listed here.

Abstract

Programmed death receptor 1, PD1, modulates the function of immune cells by providing inhibitory signals and constitutes the marker of immune exhaustion. Monitoring the level of PD1 promises a useful diagnostic approach in autoimmune diseases and cancer. Here we describe the development of an ssDNA aptamer-based molecular probe capable of specific recognition of human PD1 receptor. The aptamer was selected using SELEX, its sequence was further optimized, and the affinity and specificity were determined in biochemical assays. The aptamer was converted into a fluorescent probe and its potential in molecular imaging was demonstrated in a culture of human cells overexpressing PD1 and murine pancreatic organoids / immune cells mixed co-culture model. We conclude that the provided aptamers are suitable probes for imaging of PD1 expressing immune cells even in complex cellular models and may find future utility as diagnostic tools.

References

Yan F, Pang J, Peng Y, Molina J, Yang P, Liu S . Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells. PLoS One. 2016; 11(9):e0162925. PMC: 5017656. DOI: 10.1371/journal.pone.0162925. View

Jubel J, Barbati Z, Burger C, Wirtz D, Schildberg F . The Role of PD-1 in Acute and Chronic Infection. Front Immunol. 2020; 11:487. PMC: 7105608. DOI: 10.3389/fimmu.2020.00487. View

Prodeus A, Abdul-Wahid A, Fischer N, Huang E, Cydzik M, Gariepy J . Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers. Mol Ther Nucleic Acids. 2015; 4:e237. PMC: 4417124. DOI: 10.1038/mtna.2015.11. View

Niemeijer A, Leung D, Huisman M, Bahce I, Hoekstra O, van Dongen G . Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nat Commun. 2018; 9(1):4664. PMC: 6220188. DOI: 10.1038/s41467-018-07131-y. View

Broos K, Lecocq Q, Raes G, Devoogdt N, Keyaerts M, Breckpot K . Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy. Theranostics. 2018; 8(13):3559-3570. PMC: 6037030. DOI: 10.7150/thno.24762. View

Malicki S, Pucelik B, Zyla E, Benedyk-Machaczka M, Galan W, Golda A . Imaging of Clear Cell Renal Carcinoma with Immune Checkpoint Targeting Aptamer-Based Probe. Pharmaceuticals (Basel). 2022; 15(6). PMC: 9229018. DOI: 10.3390/ph15060697. View

Yoon S, Rossi J . Targeted Molecular Imaging Using Aptamers in Cancer. Pharmaceuticals (Basel). 2018; 11(3). PMC: 6160950. DOI: 10.3390/ph11030071. View

Ierano C, Righelli D, DAlterio C, Napolitano M, Portella L, Rea G . In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies. J Immunother Cancer. 2022; 10(3). PMC: 8900051. DOI: 10.1136/jitc-2021-004032. View

England C, Ehlerding E, Hernandez R, Rekoske B, Graves S, Sun H . Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab. J Nucl Med. 2016; 58(1):162-168. PMC: 5209640. DOI: 10.2967/jnumed.116.177857. View

10.

Duan M, Long Y, Yang C, Wu X, Sun Y, Li J . Selection and characterization of DNA aptamer for metastatic prostate cancer recognition and tissue imaging. Oncotarget. 2016; 7(24):36436-36446. PMC: 5095011. DOI: 10.18632/oncotarget.9262. View

11.

Wilson J, Zhao Y, Singer M, Spencer J, Shankar-Hari M . Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study. Crit Care. 2018; 22(1):95. PMC: 5902875. DOI: 10.1186/s13054-018-2020-2. View

12.

Bartfeld S, Clevers H . Organoids as Model for Infectious Diseases: Culture of Human and Murine Stomach Organoids and Microinjection of Helicobacter Pylori. J Vis Exp. 2015; (105). PMC: 4692704. DOI: 10.3791/53359. View

13.

Blackburn S, Shin H, Nicholas Haining W, Zou T, Workman C, Polley A . Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2008; 10(1):29-37. PMC: 2605166. DOI: 10.1038/ni.1679. View

14.

Belorgey D, Bieth J . DNA binds neutrophil elastase and mucus proteinase inhibitor and impairs their functional activity. FEBS Lett. 1995; 361(2-3):265-8. DOI: 10.1016/0014-5793(95)00173-7. View

15.

Guo X, Zhu H, Liu T, Xu X, Kong Y, Yao S . Development of Tc-conjugated JS001 antibody for in vivo mapping of PD-1 distribution in murine. Bioorg Med Chem Lett. 2019; 29(16):2178-2181. DOI: 10.1016/j.bmcl.2019.06.019. View

16.

Yoon S, Huang K, Reebye V, Mintz P, Tien Y, Lai H . Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo. Mol Ther. 2016; 24(6):1106-1116. PMC: 4923325. DOI: 10.1038/mt.2016.60. View

17.

Melancon M, Zhou M, Zhang R, Xiong C, Allen P, Wen X . Selective uptake and imaging of aptamer- and antibody-conjugated hollow nanospheres targeted to epidermal growth factor receptors overexpressed in head and neck cancer. ACS Nano. 2014; 8(5):4530-8. PMC: 4046795. DOI: 10.1021/nn406632u. View

18.

Hettich M, Braun F, Bartholoma M, Schirmbeck R, Niedermann G . High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers. Theranostics. 2016; 6(10):1629-40. PMC: 4955062. DOI: 10.7150/thno.15253. View

19.

Ehlerding E, England C, McNeel D, Cai W . Molecular Imaging of Immunotherapy Targets in Cancer. J Nucl Med. 2016; 57(10):1487-1492. PMC: 5050107. DOI: 10.2967/jnumed.116.177493. View

20.

Wang G, Liu J, Chen K, Xu Y, Liu B, Liao J . Selection and characterization of DNA aptamer against glucagon receptor by cell-SELEX. Sci Rep. 2017; 7(1):7179. PMC: 5543139. DOI: 10.1038/s41598-017-05840-w. View